DAIICHI SANKYO - Denosumab Approval In Japan: Will Contribute Bottom Lines Despite Partnering!
Daiichi Sankyo’s announced its approval of first antibody Ranmark (denosumab, fully human anti-RANKL antibody, in-licensed from Amgen, Co-promoted with AZN) for the treatment of bone complications stemming from multiple myeloma and bone metastases from solid tumors in Japan. Approval was based on global clinical studies where it not only demonstrated better efficacy data than the other bisphosphonates, but also displayed better adverse effect profile. A key feature which makes it highly convenient to the patients is it’s dosage of an injection only once in every six months (60mg) over other bisphosphonates in PMO segment. Global approval, a number of other indications underway, dose convenience, and robust PhIII data seen so far promises its market penetration and expected to generate overall sales (incl. AZN) of ¥70b by 2015 in Japan.
COMPANIES MENTIONED
DAIICHI SANKYO,
DAIICHI SANKYO,
